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Background. Women with previous gestational diabetes mellitus (GDM) have evidence of postpartum β-cell dysfunction, which
increases their risk of developing type 2 diabetes (T2DM) later in life. Elevated levels of circulating cell-free preproinsulin (INS)
DNA correlate with dying β-cells in both mice and humans. The aim of this study was to determine if cell-free circulating INS
DNA levels are higher in women with previous GDM who develop T2DM. Methods. We used droplet digital (dd) PCR to
measure the levels of cell-free circulating methylated and unmethylated INS DNA in plasma from 97 women with normal
glucose tolerance (NGT), 12 weeks following an index GDM pregnancy. Women were assessed for up to 10 years for the
development of T2DM. Results. In the follow-up period, 22% of women developed T2DM. Compared with NGT women,
total cell-free INS DNA levels were significantly higher in women who developed T2DM (P = 0 02). There was no difference
in cell-free circulating unmethylated and methylated INS DNA levels between NGT women and women who developed
T2DM (P = 0 09 and P = 0 07, respectively). Conclusions. In women with a previous index GDM pregnancy, postpartum levels
of cell-free circulating INS DNA are significantly higher in those women who later developed T2DM.
1. Introduction
Type 2 diabetes (T2DM) is a major cause of morbidity and
mortality worldwide, and the incidence is increasing, espe-
cially in low- andmiddle-income countries [1, 2]. Gestational
diabetes mellitus (GDM) is an important predictor for the
development of T2DM in later life [3]. The early identifica-
tion of those at greatest risk of developing T2DM may assist
in providing targeted lifestyle intervention and/or medica-
tions to delay the development of T2DM [4].
Cell-free circulating DNA (cfDNA), derived from dead
cells and detectable in plasma and serum, is now recognized
as a potential biomarker for a variety of diseases including
cancer [5], cardiovascular disease [6], and type 1 diabetes
[7]. With respect to type 1 diabetes, cell-free circulating
preproinsulin (INS) DNA has been commonly studied as a
marker of pancreatic β-cell death. In humans, the insulin
promoter is predominantly unmethylated in islet β-cells
and methylated in all other tissues tested [8, 9]; however,
studies in mice have shown that in response to immunologi-
cal stressors, there is an increase in β-cell methylated INS
DNA [10]. As such, elevated levels of methylated and/or
unmethylated INS DNA in people with new-onset type 1
diabetes have been reported [11, 12]. Notably, prospective
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studies have shown that circulating unmethylated INS DNA
is positively associated with the development of type 1 diabe-
tes [13]. Experimental animal models of type 1 diabetes have
also shown that significantly upregulated levels of circulat-
ing unmethylated INS DNA are detectable before the onset
of hyperglycemia [9, 14, 15]. Very recently, in islet trans-
plant recipients, β-cell death estimation using insulin
cfDNA is shown to correlate with clinical islet transplanta-
tion outcome [16].
When compared to normal glucose tolerant (NGT)
women, women with GDM have decreased β-cell function 5
years postpartum [17] which may be linked to the increased
risk of developing T2DM later in life [3]. In this study, we used
droplet digital (dd) PCR to measure postpartum cell-free
circulating INS DNA levels in women following a GDM preg-
nancy. For this study, we used plasma obtained 12 weeks fol-
lowing an index GDM pregnancy, and women were followed
for up to 10 years for the development of T2DM.
2. Methods
2.1. Participant Recruitment and Sample Collection. The
Mercy Health Human Research Ethics Committee approved
the study, and written informed consent was obtained from
all participants. The women were participants in the GDM
follow-up program, and details have been published previ-
ously [18–20]. Twelve-week postnatal blood samples were
collected in EDTA tubes, centrifuged at 1,000 g for 10min;
plasma was supplemented with 0.1mmol/l phenylmethylsul-
fonyl fluoride protease inhibitor (USB, Cleveland, OH) and
immediately stored at -80°C until assayed as detailed below.
2.2. Measurement of Cell-Free Circulating INS DNA. DNA
was isolated, processed, and analyzed following the method
described by Fisher et al. [12]. Briefly, DNA was extracted
from 50 μl of plasma (frozen unthawed aliquots) of the par-
ticipants using the QIAamp DNA blood mini kit (QIAGEN)
with 10 μg poly-A as a carrier. Of the extracted DNA, 20μl
(250-350 pg/μl) was then bisulfite converted using the EZ
DNA Methylation-Lightning kit (Zymo Research), which
converts >99.5% of nonmethylated C residues to U, while
protecting >99.5% of methylated cytosines. Droplets were
generated using the automated droplet generator, and
bisulfite-converted DNA was analyzed by droplet digital
PCR (ddPCR, Bio-Rad) using a dual fluorescent probe-based
multiplex assay. The selected probe [12] could distinguish
DNA that is differentially methylated at bp -69 of the human
insulin gene. Samples were analyzed using a QX200 Droplet
Reader and the QuantaSoft Analysis Pro Software (Bio-Rad),
to determine the concentration (copies/μl) of unmethylated
and methylated INS DNA. Plasmids for insulin cfDNA
(unmethylated, methylated, or combinations of these) were
used on each assay plate as positive controls. Inter- and
intra-assay CVs were less than 5%. The total cell-free insulin
DNA (copies/μl) represents the sum of the copies of unmethy-
lated as well as methylated insulin DNA from each sample.
2.3. Statistical Analysis. Statistical analyses were performed
using the SPSS software (v22), and significance was assigned
when P values were less than 0.05. Characteristics of the NGT
women and women with T2DM were compared using the
Mann-Whitney U test. For the cell-free INS DNA data, data
were log transformed and compared using an unpaired
Student t-test. Spearman’s correlation was used to assess
the relationship between maternal BMI and age and cell-free
INS DNA.
3. Results
Samples from a total of 97 women were used for this study,
and the clinical details are as described in Table 1. The
median follow-up period was 8.7 years, and during this time,
76 participants remained NGT while 21 developed T2DM.
The median time to the development of T2DMwas 5.8 years.
Cell-free circulating unmethylated and methylated INS DNA
levels were not different between NGT women and women
Table 1: Characteristics of the women used in this study.
Characteristics
T2DM NGT
P value1(median and IQR) (median and IQR)
(n = 21) (n = 76)
OGTT during pregnancy
Fasting (mmol/l) 5.3 (4.7-5.7) 4.7 (4.4-5.3) 0.008
1 hour (mmol/l) 10.2 (9.7-11.4) 9.7 (8.6-11.0) 0.140
2 hour (mmol/l) 9.1 (8.1-10.8) 8.6 (8.1-9.3) 0.302
Postnatal; time of sample collection
Age (years) 35.1 (31.6-37.7) 31.8 (29.2-34.89) 0.007
BMI (kg/m2) 29.1 (23.4-34.7) 24.7 (22.6-28.1) 0.024
Fasting OGTT (mmol/l) 5.0 (4.8-5.3) 4.6 (4.4-4.9) 0.001
1 hour OGTT (mmol/l) 7.2 (6.3-8.6) 6.2 (5.3-7.6) 0.030
2 hour OGTT (mmol/l) 5.3 (4.8-6.2) 5.2 (4.4-6.0) 0.313
Cholesterol 6.0 (5.0-7.1) 5.2 (4.6-6.0) 0.011
Triglycerides 1.1 (0.8-1.5) 0.9 (0.6-1.2) 0.043
NGT: normal glucose tolerant; OGTT: oral glucose tolerance test; IQR: interquartile range. 1P values are computed using the Mann-Whitney test.
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who developed T2DM (Figures 1(a) and 1(b)). On the other
hand, compared with NGT women, total cell-free INS DNA
levels were significantly higher in women who developed
T2DM (Figure 1(c)). There was no significant relationship
between maternal age or maternal BMI and cell-free circulat-
ing unmethylated and methylated INS DNA or total cell-free
INS DNA levels.
4. Discussion
Elevations of cell-free circulating unmethylated INS DNA
correlate with dying β-cells in both mice and humans
[7, 9, 11, 13–15]. In this study, we used ddPCR to determine
absolute copy numbers of cell-free circulating INS DNA
levels in plasma obtained 3 months postpartum from women
with an index GDM pregnancy. In this cohort of women, we
measured circulating unmethylated and methylated INS
cfDNA between women with a history of GDM who
developed T2DM and those who remained NGT during
the 10-year follow-up period. While cell-free unmethylated
and methylated INS DNA were higher in women who
progressed to T2DM, they did not reach statistical signifi-
cance (P = 0 11 and P = 0 07, respectively). Total cell-free
INS DNA levels, however, which represent the sum of
unmethylated INS DNA and methylated INS DNA, were
significantly higher in women who progressed to T2DM
compared to those that remained NGT.
We have previously demonstrated that postpartum
plasma C-peptide is positively associated with the devel-
opment of T2DM in women with previous GDM [19].
C-peptide is a small peptide that is cleaved from proinsulin
in the synthesis of active insulin and reflects both physiologic
insulin secretion and insulin released from damaged or dead
β-cells. Increase in unmethylated INS cfDNA is thought to
arise mainly from pancreatic β-cells, and it is thought that
this DNA is released into circulation when islet β-cells are
destroyed during disease progression [8]. In our study, how-
ever, we did not see any difference in cell-free unmethylated
INS DNA in T2DM progress versus T2DM nonprogress
suggesting no β-cell death. There are a few possible reasons
for this discrepancy. Firstly, the -69 site was chosen for these
analyses as this site is preferentially unmethylated in islet
β-cells [8, 9] and is very stable to changes in metabolic
stress such that it does not undergo methylation in
T2DM [21]. Analyzing multiple unique sites, such as by
using sequencing technologies, may possibly improve the
assay specificity but is sample and cost prohibitive. Secondly,
we analyzed samples only at one time point (~3 months post-
partum) which may miss events that occur over time. Indeed,
when compared to NGT women, women with a previous
GDM pregnancy have evidence of reduced β-cell function
five years postpartum [17].
In contrast to unmethylated INS DNA, methylated INS
DNA can arise from any nonislet β-cell tissue [8, 9]. In our
study, postpartum methylated INS cfDNA increased in
peripheral circulation of women who subsequently devel-
oped T2DM. The reason for this increase is not known. Inter-
estingly, however, in an experimental animal model of type 1
diabetes, the levels of methylated INS DNA in β-cells
increased as a direct result of proinflammatory stressors
[10]. It is unclear as to what may be the source of methylated
insulin cfDNA. Fisher et al. [12] indicate that the most likely
and convincing source of methylated cfDNA in their cohort
of individuals with or at risk of type 1 diabetes is from auto-
reactive T-cells. Although autoimmunity is not involved in
GDM, several studies [22] and a meta-analysis [23] point to
an increase in proinflammatory cytokines in GDM vs. non-
GDM pregnant mothers. Even though the exact source of
methylated cfDNA remains unknown, the increase in total
insulin cfDNA, found in our study, may reflect this increased
proinflammatory cytokine profile and/or other systemic

















































































Figure 1: Postpartum circulating cell-free INS DNA levels in women with a previous GDM pregnancy. Droplet digital PCR was used
to measure levels of cell-free circulating methylated (a) and unmethylated (b) INS DNA in plasma from 97 women, 12 weeks
following an index GDM pregnancy. After 10 years, 76 women remained NGT (controls; NGT) while 21 women developed T2DM
(T2DM). (c) Cell-free total INS DNA levels represent the sum of the unmethylated and methylated INS DNA levels. Data are presented as
mean ± sd.
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This is the first report analyzing postpartum insulin
cfDNA in a longitudinal study cohort of women with GDM
(n = 97). In an earlier cross-sectional study, 22 women with
GDM were compared with 14 non-GDM pregnant women
with an aim to assess the death of pancreatic β-cell (increased
unmethylated insulin cfDNA) in the women with GDM [24].
These investigators did not observe any increased islet β-cell
death in mothers with GDM compared to those without
GDM. Our measurements were postpartum and with an
aim to understand if increased cellular death in the immedi-
ate postpartum period was an indicator of future diabetes.
We did not observe any increase in unmethylated insulin
cfDNA copies in women who progressed to T2DM during
the study. This is in line with the gestational islet β-cell death
measurements made by Kenna et al. [24], suggesting that
there is no islet β-cell death during pregnancy or immedi-
ately postpartum but that the overall effect of GDM-related
stressors affects nonislet tissues that possibly induce a series
of inflammatory events resulting in reduced β-cell function
and progression to T2DM later in life.
It is interesting to note that it appears from the data
that there are two subgroups in the group of women
who develop T2DM: those that have increased levels of
cell-free INS DNA and those that do not. To our knowl-
edge, there is nothing different about the early postpartum
characteristics of the women with the high cell-free INS
DNA levels. Further, the women who remained NGT were
on average younger and less obese than those who devel-
oped T2DM. There was, however, no significant relation-
ship between maternal age or BMI and cell-free circulating
unmethylated and methylated INS DNA or total cell-free
INS DNA levels.
A study strength is that the increased cellular death
assessed in terms of circulating cfDNA is associated with
the development of T2DM during the next 2-9 years. Further
studies involving longitudinal analyses of circulating cfDNA
from mothers with GDM are merited. The limitations of the
study have been discussed previously [18–20] and include a
moderately small sample size, lack of normal pregnant
women as controls, and limited information on how many
of the women in each group had additional pregnancies
and what proportion of these were affected by GDM. Further
insufficient clinical information on the participants meant we
were unable to make adjustments for ethnicity or family
history of diabetes. Notably, there is a different risk for
post-GDM development of T2DM for women of different
ethnicities. Therefore, future studies must be performed
using a larger and well-characterised cohort of patients in
order to assess if cell-free circulating INS DNA can be used
to predict the development of T2DM in women with a previ-
ous GDM pregnancy. These studies should also be designed
to include normoglycemic pregnant women who did and
did not develop T2DM postpartum. These studies will also
help to inform the values required for inclusion for long-
term follow-up in terms of risk stratification.
In conclusion, in this cohort of women with previous
index GDM pregnancy, postpartum levels of total cell-free
circulating INS DNA are significantly higher in women
who go on to develop T2DM. In order to determine the
predictive value of cell-free INS DNA for the development
of T2DM, a larger study population is required.
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Additional Points
Highlights. Women with gestational diabetes have a seven-
fold higher risk of future type 2 diabetes (T2DM). The pres-
ent study demonstrates for the first time that postpartum
circulating cell-free insulin DNA levels are significantly
higher in women with gestational diabetes and could be used
to stratify those at risk of progressing to T2DM in later life.
Conflicts of Interest
There is no conflict of interest that could be perceived as
prejudicing the impartiality of the research reported.
Acknowledgments
Associate Professor Martha Lappas is supported by a
Research Fellowship from the Department of Obstetrics and
Gynaecology (University of Melbourne) and a Faculty
Fellowship from the University of Melbourne. The work
described in this manuscript was funded by the Norman
Beischer Medical Research Foundation (ML, AS, and HMG)
and Diabetes Australia (ML). AAH, MVJ, and CM are sup-
ported through a fellowship from the Juvenile Diabetes
Research Foundation Australia (JDRF), the JDRF Interna-
tional, and the Sydney Medical Foundation and Sydney Uni-
versity Summer Student program. Infrastructure/research
support to AAH through grants from the JDRF Australia,
the Rebecca L. Cooper Foundation, and the NHMRC CTC,
University of Sydney, are acknowledged. Debra Jinks, Connie
CJ Louizos, Amy Bohren, and Sonya Ristevski are thanked
for their assistance with the recruitment of the women.
Raghu Mirmira and Sarah Tersey, Indiana University, are
thanked for sharing their cfDNA protocols and plasmids.
References
[1] L. Chen, D. J. Magliano, and P. Z. Zimmet, “The worldwide
epidemiology of type 2 diabetes mellitus—present and future
perspectives,” Nature Reviews Endocrinology, vol. 8, no. 4,
pp. 228–236, 2012.
[2] J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of
the prevalence of diabetes for 2010 and 2030,” Diabetes
Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010.
[3] A. J. Lee, R. J. Hiscock, P. Wein, S. P. Walker, andM. Permezel,
“Gestational diabetes mellitus: clinical predictors and long-
term risk of developing type 2 diabetes: a retrospective cohort
study using survival analysis,” Diabetes Care, vol. 30, no. 4,
pp. 878–883, 2007.
[4] R. E. Ratner, C. A. Christophi, B. E. Metzger et al., “Prevention
of diabetes in women with a history of gestational diabetes:
effects of metformin and lifestyle interventions,” The Journal
4 Journal of Diabetes Research
of Clinical Endocrinology & Metabolism, vol. 93, no. 12,
pp. 4774–4779, 2008.
[5] H. Schwarzenbach, D. S. B. Hoon, and K. Pantel, “Cell-free
nucleic acids as biomarkers in cancer patients,” Nature
Reviews Cancer, vol. 11, no. 6, pp. 426–437, 2011.
[6] D. Antonatos, S. Patsilinakos, S. Spanodimos, P. Korkonikitas,
and D. Tsigas, “Cell-free DNA levels as a prognostic marker in
acute myocardial infarction,” Annals of the New York Academy
of Sciences, vol. 1075, no. 1, pp. 278–281, 2006.
[7] K. Zhang, G. Lin, Y. Han, J. Xie, and J. Li, “Circulating
unmethylated insulin DNA as a potential non-invasive bio-
marker of beta cell death in type 1 diabetes: a review and future
prospect,” Clinical Epigenetics, vol. 9, no. 1, p. 44, 2017.
[8] A. Kuroda, T. A. Rauch, I. Todorov et al., “Insulin gene expres-
sion is regulated by DNAmethylation,” PLoS One, vol. 4, no. 9,
article e6953, 2009.
[9] M. I. Husseiny, A. Kaye, E. Zebadua, F. Kandeel, and
K. Ferreri, “Tissue-specific methylation of human insulin gene
and PCR assay for monitoring beta cell death,” PLoS One,
vol. 9, no. 4, article e94591, 2014.
[10] J. Rui, S. Deng, J. Lebastchi, P. L. Clark, S. Usmani-Brown, and
K. C. Herold, “Methylation of insulin DNA in response to
proinflammatory cytokines during the progression of autoim-
mune diabetes in NOD mice,” Diabetologia, vol. 59, no. 5,
pp. 1021–1029, 2016.
[11] J. Lebastchi, S. Deng, A. H. Lebastchi et al., “Immune therapy
and β-cell death in type 1 diabetes,” Diabetes, vol. 62, no. 5,
pp. 1676–1680, 2013.
[12] M. M. Fisher, R. A. Watkins, J. Blum et al., “Elevations in
circulating methylated and unmethylated preproinsulin DNA
in new-onset type 1 diabetes,” Diabetes, vol. 64, no. 11,
pp. 3867–3872, 2015.
[13] K. C. Herold, S. Usmani-Brown, T. Ghazi et al., “β cell death
and dysfunction during type 1 diabetes development in
at-risk individuals,” The Journal of Clinical Investigation,
vol. 125, no. 3, pp. 1163–1173, 2015.
[14] M. I. Husseiny, A. Kuroda, A. N. Kaye, I. Nair, F. Kandeel, and
K. Ferreri, “Development of a quantitative methylation-
specific polymerase chain reaction method for monitoring
beta cell death in type 1 diabetes,” PLoS One, vol. 7, no. 10,
article e47942, 2012.
[15] M. M. Fisher, C. N. Perez Chumbiauca, K. J. Mather, R. G.
Mirmira, and S. A. Tersey, “Detection of islet β-cell death
in vivo by multiplex PCR analysis of differentially methylated
DNA,” Endocrinology, vol. 154, no. 9, pp. 3476–3481, 2013.
[16] B. L. Gala-Lopez, D. Neiman, T. Kin et al., “Beta cell death by
cell-free DNA and outcome after clinical islet transplantation,”
Transplantation, vol. 102, no. 6, pp. 978–985, 2018.
[17] T. Lekva, J. Bollerslev, K. Godang et al., “β-cell dysfunction in
women with previous gestational diabetes is associated with
visceral adipose tissue distribution,” European Journal of
Endocrinology, vol. 173, no. 1, pp. 63–70, 2015.
[18] M. Lappas, D. Jinks, A. Shub, J. C. Willcox, H. M. Georgiou,
and M. Permezel, “Postpartum IGF-I and IGFBP-2 levels are
prospectively associated with the development of type 2
diabetes in women with previous gestational diabetes melli-
tus,” Diabetes & Metabolism, vol. 42, no. 6, pp. 442–447, 2016.
[19] M. Lappas, D. Jinks, A. Ugoni, C. C. J. Louizos, M. Permezel,
and H. M. Georgiou, “Post-partum plasma C-peptide and
ghrelin concentrations are predictive of type 2 diabetes in
women with previous gestational diabetes mellitus,” Journal
of Diabetes, vol. 7, no. 4, pp. 506–511, 2015.
[20] M. Lappas, P. A. Mundra, G. Wong et al., “The prediction of
type 2 diabetes in women with previous gestational diabetes
mellitus using lipidomics,” Diabetologia, vol. 58, no. 7,
pp. 1436–1442, 2015.
[21] B. T. Yang, T. A. Dayeh, C. L. Kirkpatrick et al., “Insulin
promoter DNA methylation correlates negatively with insulin
gene expression and positively with HbA1c levels in human
pancreatic islets,” Diabetologia, vol. 54, no. 2, pp. 360–367,
2011.
[22] S. K. Abell, B. De Courten, J. A. Boyle, and H. J. Teede,
“Inflammatory and other biomarkers: role in pathophysiology
and prediction of gestational diabetes mellitus,” International
Journal of Molecular Sciences, vol. 16, no. 12, pp. 13442–
13473, 2015.
[23] J. Xu, Y. H. Zhao, Y. P. Chen et al., “Maternal circulating
concentrations of tumor necrosis factor-alpha, leptin, and
adiponectin in gestational diabetes mellitus: a systematic
review and meta-analysis,” The Scientific World Journal,
vol. 2014, Article ID 926932, 12 pages, 2014.
[24] L. A. Kenna, J. A. Olsen, M. G. Spelios, M. S. Radin, and E. M.
Akirav, “β-cell death is decreased in women with gestational
diabetes mellitus,” Diabetology & Metabolic Syndrome, vol. 8,
no. 1, p. 60, 2016.
















































































Submit your manuscripts at
www.hindawi.com
